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Copper metabolismDysmorphic features, multisystem disease, and central nervous system involvement are common symptoms in
congenital disorders of glycosylation, including several recently discoveredGolgi-related glycosylation defects. In
search for discriminative features, we assessed eleven children suspected with a Golgi-related inborn error of
glycosylation. We evaluated all genetically unsolved patients, diagnosed with a type 2 transferrin isofocusing
pattern in the period of 1999–2009. By combining biochemical results with characteristic clinical symptoms, we
used a diagnostic ﬂow chart to approach the underlying defect in patients with congenital disorders of
glycosylation-IIx. According to speciﬁc symptoms and laboratory results, we initiated additional, targeted
biochemical and genetic studies.We found a distinctive spectrumof congenital disorders of glycosylation type 2-
associated anomalies including sudden hearing loss, brain malformations, wrinkled skin, and epilepsy in
combination with skeletal dysplasia, dilated cardiomyopathy, sudden cardiac arrest, abnormal copper and iron
metabolism, and endocrine abnormalities in our patients. One patient with severe cortical malformations and
mild skin abnormalities was diagnosed with a known genetic syndrome, due to an ATP6V0A2 defect. Here, we
present unique congenital disorders of glycosylation type 2-associated anomalies, including both ATPase-related
and unrelated cutis laxa and sensorineural hearing loss, a recently recognized symptomof congenital disorders of
glycosylation. Based on our ﬁndings, we recommend clinicians to consider congenital disorders of glycosylation
in patients with cardiac rhythm disorders, spondylodysplasia and biochemical abnormalities of the copper and
iron metabolism even in absence of intellectual disability.ine aminotransferase; apo C-III,
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The congenital disorders of glycosylation (CDG) form a group of
inborn errors ofmetabolism characterized by a defective biosynthesis of
glycans,ﬁrst described by Jaeken et al. in 1980 [1]. A recent classiﬁcation
of CDGs distinguishes four major biochemical categories: three
involving protein-glycosylation (disorders of N-linked glycosylation,
O-linked glycosylation, and combined N- and O-glycosylation) and one
involving lipid-glycosylation [2]. Plasma transferrin isoelectric focusing
(TIEF) is used as a simple and reliable biochemical screening tool for
CDG associated with deﬁcient sialylation [2] (Supplementary Fig. 1).
Table 1
Genetic, clinical, and laboratory features in the historically deﬁned CDG-II group.
Genetic defect Protein Clinical features Speciﬁc laboratory features
MGAT2-CDG (CDG-IIa) N-acetylglucosaminyl-transferase II CNS, L, S, H, C –
GLS1-CDG (CDG-IIb) Glucosidase I CNS, L, S, R, GI Abnormal levels of a
tetrasaccharide in urine
SLC35C1/FUCT1-CDG (CDG-IIc) Solute carrier family 35, member
C1/GDP-fucose transporter 1
CNS, SS, B, I –
B4GALT1-CDG (CDG-IId) β-1,4-galactosyltransferase CNS, L, C, M Lack of SLeX expression in
neutrophils
SLC35A1-CDG (CDG-IIf) CMP-sialic acid transporter I, C Lack of SLeX expression in
neutrophils
COG1-CDG (CDG-IIg) COG 1 CNS, L –
COG4-CDG COG 4 CNS, L, R, I –
COG5-CDG COG 5 CNS, L –
COG6-CDG COG 6 CNS, L Vitamin K deﬁciency
COG7-CDG (CDG-IIe) COG 7 CNS, L, S, H, C, M I, GI,
cutis laxa, hyperthermia
–
COG8-CDG (CDG-IIh) COG 8 CNS, L, S, C, M –
ATP6V0A2-CDG ATP6V0A2 CNS, S, cutis laxa –
According to the new nomenclature, the name of the gene followed by the CDG sufﬁx is used. B indicates hematological; C, coagulopathy; CNS, central nervous system; COG,
conserved oligomeric Golgi complex subunit; GI, gastro-intestinal; H, heart; I, immunological; L, liver; M, muscle; R, respiratory; S, skeletal abnormalities; SLeX, Sialyl–Lewis X
ligand.
2 EUROGLYCANET, Diagnosis and Research Management System (www.euroglycanet.
org/uz/Database).
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disorders, hypoglycosylated isoforms are elevated and tetrasialotrans-
ferrin is decreased. The glycosylation route comprises the cytoplasm, the
endoplasmic reticulum, and the Golgi apparatus. Depending on the
localization of a defect, two isofocusing patterns can be distinguished:
the so called type 1 pattern demonstrates increases of even (2 and 0)
sialotransferrin bands (previously CDG-I), and the type 2 pattern,
showing additional uneven (3 and 1) sialotransferrin bands (previously
CDG-II [2]). This classiﬁcation, based on the TIEF pattern, relates to
N-glycosylation diseases, found by the initial screening test in patients
with a suspected CDG. According to preceding nomenclature, however,
not only patients with a CDG type 2 pattern were labeled as CDG-II
defects but also thosewith a few additional CDG formswith normal TIEF
as well, based on their underlying defect in Golgi or Golgi-associated
proteins [3]. Unsolved patients with type 2 TIEF patternwere labeled as
CDG-IIx (MIM 212067) [4].
In addition to parts of the N-glycan biosynthesis pathway, the Golgi
apparatus houses the full mucin type O-glycan biosynthetic pathway.
Plasma apolipoprotein C-III (apo C-III) isofocusing has been developed
to evaluate O-glycan biosynthesis [3] (Supplementary Fig. 1), a useful
tool also in combined N- and O-glycan biosynthesis defects [3].
Some of the CDG patients show not only abnormal N-linked but also
abnormal O-glycosylation. Other Golgi-related glycosylation defects,
however, likemuscle-eye-brain disease, Schneckenbecken dysplasia, or
multiple cartilaginous exostoses, do not show abnormal TIEF. Due to the
emerging number of combined and isolated O-glycosylation defects, a
consensus for a novel nomenclature, based on genetic etiology, became
essential [2].
In the past couple of years, several novel CDG defects have been
described with a type 2 TIEF pattern, some of them historically carrying
the name CDG-II (COG7-CDG/CDG IIe, COG1-CDG/CDG IIg, etc.), while
the most recently discovered types were labeled as COG5-CDG and
COG6-CDG [2,5–11]. Neurologic involvement is frequent in both CDG-I
and CDG-II defects [2,3,5–11]. COG7-CDG typically presents with
profound development delay, microcephaly, swallowing difﬁculties,
failure to thrive, and distal arthrogryposis [8,9] (Table 1). Another
interesting example with distinctive CNS symptoms is ATP6V0A2-CDG,
causing autosomal recessive cutis laxa syndrome type II (ARCL-type-II,
MIM 219200), a disorder of sagging skin, dysmorphic features,
developmental delay, and unique cortex malformations [5,6], and a
combined N- and O-glycosylation defect [12–14].
Recently, the number of defects associated with a CDG type 2
pattern has been more than doubled [15,16]. Apart from the central
nervous system, hematologic, and liver involvement in both types, thephenotype of the newly discovered defects is quite different from the
well known clinical pattern in CDG-I (Table 1). Classic CDG-I features,
like inverted nipples, hypothyroidism, or strabismus are less common
in patients with a type 2 TIEF pattern.
In the European database EUROGLYCANET,2 for glycosylation
disorders, approximately 80% of patients show a type 1 pattern. With
advancing biochemical techniques, the primary molecular genetic
defect has been elucidated in the majority of CDG-I cases. In contrast,
no comprehensive analytical or biochemical techniques are available to
identify and delineate the primary defects in patients with a TIEF type 2
pattern and suspected Golgi-related glycosylation defects. Thereby, the
vast majority of these cases (80% of CDG-II patients based on
EUROGLYCANET, 2010) is still classiﬁed as unsolved CDG-IIx (MIM
212067).
2. Patients and methods
All patients were evaluated according to standard diagnostic
procedures for a suspected disorder of protein glycosylation.
Patient 1 was not fully evaluated due to an early lethal course.
2.1. Clinical patient characteristics
Patients 1 and 2 were brothers. They presented with recurrent
infections, anemia, hepatosplenomegaly, severe thrombocytopenia,
disturbed coagulation and liver function tests, and increased activity
of lysosomal enzymes in plasma. Patient 1 had severe hypotonia,
strabismus, and developmental delay, the latter also present in patient
1. The female patient 3 showed generalized hypotonia, macrocephaly
with large fontanel, psychomotor retardation, joint-hyperlaxity,
intermittently elevated serum transaminases, and leucopenia, with-
out a history of infections. The male patient 4 showed normal
development until the age of 13 years when he experienced a sudden
cardiac arrest. He developed epilepsy and became physically and
mentally disabled. Hemostasis and liver function were abnormal.
Albuminuria and hypoglycemia were noted (Table 2; for extended
description, see Supplementary materials). The male patient 5
showed multiple dysmorphic features and congenital genital abnor-
malities. He had hypothyroidism, abnormal coagulation, liver dys-
function, decreased serum ceruloplasmin and copper levels, and
elevated creatine kinase (CK). Subsequently, he developed myopia
Table 2
Clinical features.
Patient 1 ♂ Patient 2 ♂ Patient 3 ♀ Patient 4 ♂ Patient 5 ♂
Age of onset 3 months (deceased 15months) 5 months 3 months 13 years Neonatal
Ethnicity/consanguinity Turkish/+ Turkish/+ Greek/suspected German/− Polish/−
Dysmorphic features/congenital
anomalies
– – Macrocephaly, large fontanel – Upslanting palpebral ﬁssures, epicanthal folds, thin nasal
bridge, bilateral inguinal hernias, micropenis, testes migrans
Skeletal/limb anomalies – – Hyperlaxity of the joints – Clinodactyly
PMR/hypotonia +/− −/+ +/+ +/− −/−
Hepatic involvement HSM, liver cirrhosis, ↑TA, ↑AP, ↑bili HSM, liver cirrhosis, ascites,
↑TA, ↑AP, ↑bili
↑TA, ↑AP ↑TA HM, pancreatic steatosis, ↑neonatal icterus, ↑TA
Hematological involvement,
coagulopathy
Anemia/thrombopenia, ↑TT,
↓ﬁbrinogen
Thrombopenia,
↑APTT, ↑TP, ↑TT,
↑INR
Leucopenia Recurrent GI-bleedings/thrombosis,
↑APTT, ↓FII, ↓FV, ↓FVII, ↓FIX, ↓FXI,
↓protein C/S, ↓AT-III
↓AT-III, ↓protein C/S
Neurological/psychiatric
involvement
−/− −/− −/ADHD Focal motor seizures/− Bilateral sensorineural deafness, sudden unilateral deafness/−
Cerebral MRI NA Agenesis CC Normal Slight ventriculomegaly/left
temporal atrophy
Widening of Virchow–Robin spaces (occipital, parietal, frontal),
hyperintense signal (T2) occipital horns of lateral ventricles
Cardiac involvement – – – Sudden cardiac arrest, VES,
normal echocardiography
–
Ophthalmological involvement – Divergent strabismus – – Hypermetropia, peripheral retinal pigmentation
Recurrent infections Salmonella typhii GE, chronic
hepatitis C infection
Chronic hepatitis C infection – – –
Other laboratory abnormalities ↑Lysosomal enzymes ↑Lysosomal enzymes Hypoglycemia, ↓α1-AT, albuminuria ↑↓Serum copper and ceruloplasmin, ↑CK, ↓T3, ↓FT4
Patient 6 ♀/patient 7 ♂ Patient 8 ♂ Patient 9 ♀
Age of onset Neonatal Neonatal Neonatal
Ethnicity/consanguinity Turkish/+ Czech/− German/−
Dysmorphic features/congenital anomalies Mild Microcephaly, ptosis, blue sclerae,
downslanting palpebral ﬁssures
Microcephaly, dolichocephaly, gothic palate, blepharophimosis,
cutis laxa, hypertrichosis, arachnodactyly, duodenal atresia and
intestinal malrotation, bilateral inguinal hernias
Pierre–Robin sequence, hypotelorism,
crowded teeth, short stature
Skeletal/limb anomalies Delayed bone maturation Talipes equinovarus adductus, brachymetatarsia, congenital hip
dysplasia, subluxation thumbs/hyperlaxity joints
Delayed bone maturation
PMR/hypotonia +/+ +/+ −/+
Hepatic involvement Cholestasis, ↓ceruloplasmin, ↑LDH/↑TA ↑TA, ↓LDH ↑TA
Hematological involvement, coagulopathy ↓Protein S, ↓AT-III, ↓ﬁbrinogen, ↓FIX ↑APTT, ↑PT, anemia ↓AT-III
Neurological /psychiatric involvement Physical contact aversion Hyperkinesia, dyslalia/aggression,
self-mutilation
−/−
Sleep disorder Ataxia
Cerebral MRI ↓Occipital myelinization Normal Hypogenesis posterior CC NA
Cardiac involvement – – DCM, MI, TI (SF, 22%)
Ophthalmological involvement – ↓Vision, myopia, nystagmus –
Recurrent infections – Upper respiratory tract infections –
Other laboratory abnormalities ↑CK Hypoglycemias, ↑CK, ↓LH, ↓FSH, ↓IGF-1, ↓TBG, ↓estradiol –
α1-AT indicates alpha1-antitrypsine; ADHD, attention deﬁcit hyperactivity disorder; ALP, alkaline phosphatase; APTT, activated partial thromboplastin time; AT-III, antithrombin-III; ASD, atrial septum defect; bili, bilirubin; CC, corpus
callosum; CK, creatinine kinase; DCM, dilated cardiomyopathy; F, factor; FSH, follicle stimulating hormone; FTT, failure to thrive; Fe, iron; GE, gastroenteritis; GI, gastro-intestinal; HM, hepatomegaly; IGF-1, insulin like growth factor 1; INR,
international normalized ratio; HSM, hepato-splenomegaly; LDH, lactate dehydrogenase; L, left; LH, luteinizing hormone; MI, mitral insufﬁciency; PMR, psychomotor retardation; R, right; SF, shortenings fraction; TA, transaminases; T3,
triiodothyronine; T4, thyroxine; TBG, thyroxine binding globulin; TI, tricuspid insufﬁciency; TT, thrombin time; VES, ventricular extrasystole.
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694 M. Mohamed et al. / Biochimica et Biophysica Acta 1812 (2011) 691–698and retinitis pigmentosa. Prepubertally, his bilateral hearing loss
required hearing aids. Right-sided sudden deafness occurred at the
age of 13 years. Hearing was restored by cochlear implant and he
attends a regular school. Patients 6 and 7 (sister and brother) showed
cholestasis after birth. Patient 6 had elevated CK, alanine amino-
transaminase and aspartate aminotransaminase (ASAT and ALAT)
levels, and disturbed clotting parameters. She was diagnosed at the
age of 10 years with chronic liver disease, also showing mild
dysmorphic features, relative microcephaly (Fig. 2), generalized
muscular hypotonia, and a severe sleeping and behavioral disorder.
Her brother (patient 7) is additionally known with skeletal
dysplasia, ptosis (Fig. 2), and a more severe psychomotor retardation.
The male patient 8 has previously been reported [17]. In the following
years, wrinkled skin on his abdomen and neck becamemore apparent
(Fig. 2). He developed a behavioral disorder with aggression and self
mutilation. Subsequently, he showed severe myopia, sensorineural
hearing loss, severe mental retardation, and an expressive language
disorder. The female patient 9 had a Pierre–Robin sequence (Fig. 2),
generalized muscular hypotonia with elevated CK, dilated cardio-
myopathy, and delayed motor development. The hypotonia improved
signiﬁcantly over the years. At 15 years, she has short stature,
hypogonadotrophic hypogonadism, and a high normal intelligence.
The male patient 10 had dysmorphic features, short stature, and
kyphoscoliosis. Vision was impaired due to glaucoma. His motor
development was delayed. Severe anemia required transfusion.
Currently, he is 17 years old and attends regular school. Patient 11Fig. 1. T1 weighed sagittal MRI images demonstrating frontal cobblestone like cortical dysg
horizontal image showing bilateral frontal polymicrogyria, enlarged Virchow–Robin spaces (
skin (d) in patient 11.had wrinkled skin of the abdominal region (Fig. 1d) and other
dysmorphic features. He had amotor and speech developmental delay
and showed complex partial seizures. At the age of 14 years, he was
mentally retarded.
2.2. Additional clinical evaluation
Hand X-rays were performed in three patients to determine bone
age, in accordance with the Greulich and Pyle atlas. All investigations
including brain imaging (MRI and ultrasound), visual evoked potentials
(VEP), electromyography (EMG) and electroencephalography (EEG),
liver biopsies, and skeletal imaging were performed upon clinical
indication.
2.3. Laboratory investigations
Standard laboratory investigations included full blood count,
transaminases (ALAT, ASAT), alkaline phosphatase (ALP), gamma-
glutamyltransferase (γ-GT), infection parameters, hemoglobin, crea-
tine kinase, lactate dehydrogenase (LDH), and urine reduction.
Investigations performed upon indication were serum bilirubin,
copper, ceruloplasmin, iron, cholesterol, triglycerides, coagulation
factors, coagulation tests, ceruloplasmin, hormones, amino acids, and
activity of lysosomal enzymes in plasma. Upon indication, organic
acids and oligosaccharides were evaluated in urine. Also, upon
indication, hepatitis A, B, and C antibodies were evaluated.enesis (a) and no signiﬁcant cerebellar hypoplasia in ATP6V0A2-CDG (b). T2 weighed
arrow) by symmetrical cobblestone like cortical dysgenesis (c), andwrinkled abdominal
Fig. 2. (a, b, e) Patient 7 presented with microcephaly, bilateral ptosis, blue sclerae, downslanting palpebral ﬁssures, scapula alatae, and platyspondyly. (c, d) His sister, patient 6,
showed mild dysmorphic features like a ﬂat face, hypertelorism, and relative microcephaly. (f, g) Patient 9 presented with a Pierre–Robin sequence, a ﬂat face, hypertelorism,
hypogonadotropic hypogonadism and cardiomyopathy. (h–l) A syndrome like presentation in patient 8 with marked hypotonia (h); cutis laxa (i); pes adductus with hypoplastic
small toe (j); clinodactyly of the ﬁfth ﬁnger, low insertion of the thumb, camptodactyly (k); and extended hypertrichosis of the back (l).
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All patients were included with a TIEF showing a type 2 pattern.
Secondary causes of hypoglycosylation were evaluated using clinical
and dietary anamnesis, urine analysis, and if indicated by blood
culture, genetic studies and plasma protein mass spectrometry. Lipid-
linked oligosaccharides (LLO) analysis used in three inconclusive
initial TIEF proﬁle cases conﬁrmed CDG type 1. To evaluate Golgi-related mucin-type O-glycosylation defects, isoelectric focusing of
apoC-III was performed as described by Wopereis et al. [3]. MALDI
mass spectrometry of plasma N-glycans was performed to exclude
MGAT2-CDG, SLC35C1-CDG, and B4GALT1-CDG [18]; tetrasaccharides
in urine were measured to screen for GLS1-CDG [19] and neutrophil
surface sialyl-Lewis-X ligand for SLC35C1-CDG and SLC35A1-CDG
[20]. Direct sequencing was used to evaluate COG defects (COG1-
CDG–COG8-CDG) and ATP6V0A2-CDG (Supplementary methods).
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Table 2 provides an overview of clinical, biochemical, and metabolic
ﬁndings.
3.1. Additional clinical investigations
BEAP showed severe bilateral sensorineural hearing loss in patient
8 (55/65 dB). In patient 5, the audiogram showed sensorineural
deafness of the right ear and a hypoacusis (70 dB) of the left ear. In
three patients withmuscle weakness, EMG showed normal results. An
EEG was performed in four cases: one was normal, two showed
encephalopathy with generalized epileptic activity (patients 4 and 8),
and one with bilateral frontotemporal focal activity (secondary
generalized; in patient 11). VEP was severely abnormal in patient 5
and showed a normal result in patient 10.
MRIwas performed in ten patients. Head ultrasoundwas performed
in patient 1.
In ﬁve patients, no abnormalities were detected (patients 1, 3, 7, 9,
and 10). Patients 2 and 8 showed partial agenesis of the corpus
callosum and patient 6 decreased myelinization around the occipital
horn of the ventricle. In patient 4, widened ventricles and atrophy on
the left fronto-temporal cerebral quadrant were seen. Patient 5
showed brain atrophy and small areas of increased paraventricular
occipital signal intensity. Patient 11 had bilateral frontal cobblestone
like cortical dysgenesis (Fig. 1c).
3.2. Histology
In patients 1 and 2, a liver biopsy showed chronic hepatitis,
micronodular changes, and necrosis. (In this phase, the hepatitis
serology did not support active infection.)
3.3. Biochemical investigations
Liver function was abnormal in nine patients (Table 2). Patients 5
(increased TSH and decreased free T4) and 9 (decreased LH, FSH, and
oestradiol) had endocrine abnormalities. Full blood count abnormalities
were found in patients 1, 2, 3, and 10 (thrombopenia, leucopenia, and
anemia). Serum copper was diminished and iron level ﬂuctuated in
patient 5. Coagulation was disturbed in eight patients (decreased
clotting factors, abnormal coagulation tests, or thrombotic events).
Ceruloplasmin was decreased in patients 5, 6, and 7. Activity of
lysosomal enzymes in serum were measured in four patients, of
which two patients showed elevated levels (patients 1 and 2) and two
showed normal levels (patients 3 and 6).
Organic acids and oligosaccharides in urine were measured in ﬁve
patients: results were normal in four patients (3, 5, 8, and 9) but
abnormal in patient 2 with elevated galactose levels. Sialyl–Lewis X
expression in patient 8 was normal, ruling out the probability of
SLC35A1-CDG.
3.4. Glycosylation analysis
Abnormal TIEF proﬁles led to exclusion of GLS1-CDG and SLC35C1-
CDG since these subtypes give normal TIEF proﬁles. The disialo TIEF
pattern was seen in eight patients and two patients showed an asialo
pattern. Of the eight patients with a disialo pattern, one was not
evaluated due to early death, two had an apoC-III0 proﬁle, and six, an
apoC-III1 proﬁle, which indicates a combined defect in N- and O-
glycosylation [16]. Of the two patients with the asialo TIEF pattern, one
showed a normal apo C-III-proﬁle and the second showed an apoC-III0
proﬁle (Supplementary Fig. 1). Lipid-linked oligosaccharides (LLO)
analysis was normal. Mass spectrometry analysis of N-glycans revealed
a Golgi-related defect in 8 of the 9 analyzed patients (increase in
truncated glycans associated with decreased triantennary structures),making MGAT2-CDG, SLC35C1-CDG, and B4GALT1-CDG unlikely.
Western blot analysis for COG subunits was normal.
3.5. Genetic analysis
High resolution karyotype and/or array CGHwas normal. The results
of sequencing for the eight COG subunit geneswere normal. In patient 5,
genetic investigations ruled out Pendred syndrome (suspected based on
hearing loss in combination with hypothyroidism). Genome wide
linkage analysis (homozygosity mapping) was performed in patients 6
and 7. This has not resulted in a candidate gene due to abundance of
large homozygous regions. We also ruled out all genes known to be
involved in the glycosylation pathway in the homozygotic regions.
ATP6V0A2 mutation analysis was noncontributory in patient 8 and
showed two novel mutations in a compound heterozygous form
(c1101delC/c1562_1563delins9) in patient 11.
4. Discussion
The surprising discovery of the ATP6V0A2 defect in autosomal
recessive cutis laxa type II presenting as a glycosylation defect led to a
rapid increase in the number of patients diagnosed with a type 2 TIEF
pattern. This taught us that, once a distinct phenotype is associatedwith
CDG, systematic screening leads to large additional numbers of patients.
To date, eight patientswith CDG-IIx have been published as case-reports
[21–25] (one of these patients was diagnosed since the original report
with COG4-CDG) [22]. This is in great contrast to the rapidly expanding
CDG-IIx group. These genetically unsolved patients have been reported
with a mild psychomotor retardation, infections (hemolytic uremic
syndrome), failure to thrive and facial dysmorphy [21], chronic diarrhea,
progressive liver cirrhosis, and recurrent infections [22]; a lethal case,
withpsychomotor retardationandbleeding tendency [23]; anadult case,
with unexplained chronic hypertransaminasemia with decreased
clotting factors [24]; and a cohort of four patients with hypertransami-
nasemia, coagulopathy, and steatosis [25].
The combination of liver and CNS involvement is common in CDG. In
our own cohort, 9 out of 11 patients showed liver involvement. Liver
problems varied from slightly elevated transaminases without clinical
consequence to hepatic coma leading to death. Central nervous
symptoms are characteristic features of CDG. Interestingly, two children
in our study group showed no mental retardation. Of the two children
with clinical epilepsy, one presented with seizures only after cardiac
arrest.MRI changeswerediagnostic in patient 11, showingcobble-stone
likebrain dysgenesis (frontal polymicrogyria; Fig. 1). Eye involvement is
well known in CDG-I but unusual in CDG-II. We found ophthalmologic
abnormalities including retinitis pigmentosa (patient 5), glaucoma
(patient 10), and severe myopia (patient 8). A unique neurological
presentation was observed in the most complex patient (patient 5). He
suffered from hypoacusis which suddenly developed to acute unilateral
deafness. Sensorineural hearing loss has been recently associated with
CDG-I in RFT1-CDG [26]. In CDG-II, sudden deafness had never been
describedbefore. Patient 8 and patient 11had abdominalwrinkled skin/
cutis laxa and CNS malformations. Compared to the ATP6V0A2-related
phenotype, conﬁrmed in patient 11 but not in patient 8, the latter
developed progressive skinwrinkling through the course of the disease,
in association with sever hypermetropia, inguinal hernias, joint
deformations, and hypertrichosis.
Cardiomyopathy and rhythm disorders have not previously been
associated with CDG-II. Patient 4 suffered a sudden cardiac arrest, most
likely due to the combination of an underlying rhythm disorder
(ventricular extrasystoles). Patient 9 showed a dilated cardiomyopathy
with left sided heart failure and Wolff–Parkinson–White syndrome.
Patient 10 had several skeletal and joint abnormalities (hypoplasia ﬁfth
ray hands, pectus excavatum, kyphoscoliosis, abnormal ossiﬁcation/
lysis of cervical vertebrae), in combination with hernias. The features
were not comparable with a known skeletal dysplasia [29]. Another
Fig. 3. Diagnostic ﬂowchart for patients diagnosed with a CDG type 2 pattern. Once a type 2 TIEF proﬁle has been conﬁrmed and secondary glycosylation defects are ruled out, the
pattern is matched to known type 2 proﬁles. If these do not match, isoelectric focusing of apoC-III protein is performed for Golgi related secretory O-mucin type defects. Mass
spectrometry (MS) of plasma glycans is used to exclude MGAT2-CDG or B4GALT1-CDG because these two types have distinct MS proﬁles. Western blot analysis and sequencing of
COG genes can lead to diagnosing a COG defect. The use of homozygosity mapping, especially in consanguineous cases and whole genome analysis, can be implemented
simultaneously.
697M. Mohamed et al. / Biochimica et Biophysica Acta 1812 (2011) 691–698three patients had delayed bone maturation, platyspondyly, and/or
decreased bone density, demonstrating common skeletal involvement
in CDG-IIx.
Patient 11 was diagnosed with a so far undescribed mutation in
ATP6V0A2 based on phenotyping combined with apoC-III results,
demonstrating the success of our approach. Interestingly, the other
patientwith cutis laxa and CDG-II did not carry amutation in ATP6V0A2.
Endocrine abnormalities are common in CDG-I, especially with
decreased TBG and total T4 levels. Patient 5 had hypothyroidism with
goiter, not previously reported in CDG-II. Patient 9 interestingly
showed a hypogonadotrophic hypogonadism in combination with
growth delay and decreased IGF-1 levels [34]. Coagulopathy deﬁned
as decreased clotting factors, thrombopenia, and prolonged bleeding
time was present in seven patients. Some of these patients had
bleedings after minimal invasive medical procedures, even with only
slightly decreased clotting factors. CDG thus should be considered in
unexplained bleeding disorders. The diminished serum copper and
ceruloplasmin levels in two patients are unexplained and might be a
consequence of abnormal Golgi transport.
Increased activities of lysosomal enzymes in plasma are present in
most CDG-I but not in CDG-II [27], except for COG7-CDG [28]. Bothpatients died shortly after birth and showed outspoken dysmorphic
features and skeletal anomalies, in contrast with our patients 1 and 2
who also showed increased activity of lysosomal enzymes. The exact
mechanism leading to increased activity of lysosomal enzymes
remains unclear.
Mass spectrometry has a growing signiﬁcance in CDG diagnostics,
especially in MGAT2-CDG, SLC35C1-CDG, and B4GALT1-CDG. Direct
genetic approaches, like direct sequencing for known genes and homo-
zygosity mapping, in combination with clinical/biochemical grouping,
have been proven effective in elucidating underlying genetic defects
(ATP6V0A2-CDG, DPM3-CDG, and SRD5A3-CDG) [14,30,31]. Clinical
phenotyping should be included early on to decide on the diagnostic
approach in CDG patients with a type 2 pattern (Fig. 3). Pathognomic
features, such as cobble-stone like cortical dysgenesis with skin
wrinkling [13,32,33] or severe microcephaly with adducted thumbs
[9], are key to the diagnosis. The combination of neurological symptoms
and liver dysfunction is highly suggestive for congenital disorders of
glycosylation, but normal psychomotor development does not exclude
CDG-II.
Supplementarymaterials related to this article can be found online
at doi: 10.1016/j.bbadis.2011.02.011.
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